Trials / Completed
CompletedNCT03727724
Afatinib and Cetuximab in Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Positive Non-small-cell Lung Cancer
Phase II Single Arm Study of Afatinib in Combination With Cetuximab in EGFR Exon 20 Insertion Positive Non-small-cell Lung Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 37 (actual)
- Sponsor
- The Netherlands Cancer Institute · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a single arm open-label multi-center phase II study, investigating disease control rate after 18 weeks of treatment with afatinib/cetuximab combination therapy in patients with advanced non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Afatinib | Tablet |
| DRUG | Cetuximab | Injection |
Timeline
- Start date
- 2018-12-04
- Primary completion
- 2022-09-06
- Completion
- 2022-09-06
- First posted
- 2018-11-01
- Last updated
- 2023-10-18
Locations
4 sites across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT03727724. Inclusion in this directory is not an endorsement.